Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

MOUNTAIN VIEW, Calif., Nov. 8, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology (ACR).  CCX354 is an orally-active small molecule that specifically targets and inhibits the chemokine receptor known as CCR1, which is implicated in the development and progression of rheumatoid arthritis (RA).  Results showed that CCX354 was safe and well tolerated by patients with RA in this clinical trial, and demonstrated clinical and biological activity at a dose of 200 mg once daily.  These data were highlighted today in a late-breaker oral presentation in Chicago entitled "Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase II Rheumatoid Arthritis Study".

"The initial cloning and characterization of CCR1 as well as the chemokine known as RANTES, one of the main ligands for CCR1, was accomplished by the founder of ChemoCentryx over twenty years ago," stated Paul-Peter Tak, M.D., Ph.D., Lead Investigator and Professor at AMC/University of Amsterdam, currently also Senior Vice President/Head, Therapy Area ImmunoInflammation at GlaxoSmithKline.  "Although there has been strong evidence implicating CCR1 in the pathology of RA, this is the first time that an investigational CCR1 antagonist has successfully demonstrated clinical efficacy in patients with this disease."

The results reported from this study, known as the CARAT-2 clinical trial, show that patients who met inclusion criteria at the start of dosing (Day 1 eligible) had an ACR20 response at Week 12 of 56% in patients receiving 200 mg CCX354 once daily compared to 44% in patients receiving 100 mg twice daily, and 30% in patients receiving placebo. The difference between 200 mg once daily and placebo was statistically significant (p=0.014). The decrease in CRP, a marker of inflammation, was statistically significant in the 200 mg QD group com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Zacks.com announces the list of stocks ... Research analysts discuss the latest news and events impacting stocks ... include the Biogen (Nasdaq: BIIB - Free Report ), Gilead ... PBYI - Free Report ), AbbVie (NYSE: ABBV ... Free Report ). Today, Zacks is promoting its ...
(Date:7/31/2014)... YORK , July 31, 2014 TB ... better, faster and affordable treatments for tuberculosis (TB), announced ... Vice President, Market Access. Ms. Robertson joins the organization ... company,s business in Sub-Saharan Africa and Eastern ... oversee the TB Alliance,s efforts to ensure beneficial new ...
(Date:7/31/2014)... und KISSING, Deutschland, 31. Juli ... und Distributor eines computerunterstützten („robotischen") Koloskopie-Systems für ... (Homi) Shamir , ein weltweit anerkannter Manager ... und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener globaler Visionär ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3
... 4, 2011 Bioness Inc. today ... of the FASTEST study to further examine the impact of ... drop as a result of stroke. The FASTEST study aims ... System over standard therapy with an ankle-foot orthosis (AFO), and ...
... Inc. (NASDAQ: NBIX ) today announced that it ... for elagolix and next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. ... with the FDA, the outcome of which generated a $20 ... event brings the total milestones achieved by the Company in ...
Cached Medicine Technology:Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study 2Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement 2
(Date:7/31/2014)... 31, 2014 Researchers from the ... largest study to date comparing the ... or traditional letter referral systems in a real-life ... patent pending iDoc24® technology provided faster and more ... while potentially eliminating unnecessary visits. iDoc24® is a ...
(Date:7/31/2014)... Reserve University medical and nursing school researchers hope ... patients who participate in clinical trials, a critical ... preventions. , For various reasonsincluding a lack of ... of cancer patients take part in trials of ... cancer patients who are eligible still don,t enroll, ...
(Date:7/31/2014)... Thousands of independent community pharmacists, ... have come together today to kick off ThoughtSpot ... , "ThoughtSpot 2014 is Good Neighbor Pharmacy’s annual ... to help their businesses thrive," stated AJ Caffentzis, ... long-standing commitment to independent community pharmacies, and at ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... Web Technologies, an ISO 9001:2008 certified internet marketing firm, ... Designing. In order to make this service affordable for ... in return of the service. , Web Programming ... study about the world of brochure designing and likely ...
(Date:7/31/2014)... 2014 Recently, Agebc.com, a popular online shop ... its new selection of trendy mother of the bride ... at promotional prices now, up to 68% off. , ... the new range of mother of the bride dresses. We ... clients. So far, our online shop has received thousands of ...
Breaking Medicine News(10 mins):Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 2Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 3Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 4Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 2Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 3Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 2Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Mother of the Bride Dresses Now Available With Great Discounts at Agebc.com 2
... Inc. (OTC Bulletin Board: NVLX), today announced that it will ... at 4:30 PM Eastern Time to discuss current trends in ... of the Last Shot Hangover Remedy. , , ... extraordinary progress towards achieving our stated goals for the current ...
... ... launches a new national television advertising campaign calling on Congress to put an end ... ... -- Autism Speaks, the nation,s largest autism science and advocacy organization, today launched a ...
... more aggressive cancer, study contends , WEDNESDAY, July 8 (HealthDay ... prescribing the drug finasteride to men at risk for prostate ... when trying to decide whether to use the drug, which ... in five men who take it. However, findings from the ...
... mother and she,ll tell you that raising a preschooler is ... like to bring up a child with autism or a ... Center asked mothers about their experiences and found that moms ... and psychological distress than mothers of children with developmental delay. ...
... Like an estimated 5 million other Americans, Barry Simonis had ... risk of stroke and causes the most important muscle in ... cardiovascular surgeon John Johnkoski, M.D., recently performed an advanced surgical ... that plagued the Rosholt resident for more than 10 years. ...
... avoid arthritis in adolescence , WEDNESDAY, July 8 (HealthDay News) ... reduce their risk of developing early arthritis, says a new ... defect in newborns -- occurs when a hip joint is ... with the condition can develop arthritis of the hip when ...
Cached Medicine News:Health News:Nuvilex, Inc. Announces Business Update Conference Call 2Health News:Nuvilex, Inc. Announces Business Update Conference Call 3Health News:Autism Speaks Launches TV Ad Campaign Calling on Congress to End Insurance Discrimination Against Children with Autism 2Health News:Autism Speaks Launches TV Ad Campaign Calling on Congress to End Insurance Discrimination Against Children with Autism 3Health News:Prostate Drug Appears Safer Than Thought 2Health News:Mothers of children with autism have higher parental stress, psychological distress 2Health News:Mothers of children with autism have higher parental stress, psychological distress 3Health News:Advanced Heart Procedure Treats Growing Problem 2Health News:Advanced Heart Procedure Treats Growing Problem 3Health News:Screen All Newborns for Hip Dysplasia, Study Urges 2
Hand surgery basic instrument set with round handled instruments...
Rhoton microscopic forceps, straight...
Quick release, easy to close 2" webbing and buckle. Available in teal, royal, red, purple, and maroon nylon stain-resistant fabric or navy nylon reinforced vinyl....
Velcro closures on each side to more evenly distribute the weight. Available in teal, royal, red, purple, or maroon nylon stain-resistant fabric or navy nylon reinforced vinyl....
Medicine Products: